BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abd Elrazek AE, Bilasy SE, Elbanna AE, Elsherif AE. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore). 2014;93:e204. [PMID: 25526438 DOI: 10.1097/md.0000000000000204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ahmed OA, Kaisar HH, Badawi R, Hawash N, Samir H, Shabana SS, Fouad MHA, Rizk FH, Khodeir SA, Abd-Elsalam S. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 2018;11:295-8. [PMID: 29535545 DOI: 10.2147/IDR.S153060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
2 Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol 2018; 24(24): 2555-2566 [PMID: 29962813 DOI: 10.3748/wjg.v24.i24.2555] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
3 Kamel S, Elessawy H, Ashraf O, Elbaz A, Dabbous H, El-sayed M, Ali S, Kamel H. Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients. Gastroenterology Insights 2021;12:336-46. [DOI: 10.3390/gastroent12030031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Abdel-Aty M, Fouad M, Sallam MM, Elgohary EA, Ismael A, Nawara A, Hawary B, Tag-Adeen M, Khaled S. Incidence of HCV induced-Esophageal varices in Egypt: Valuable knowledge using data mining analysis. Medicine (Baltimore) 2017;96:e5647. [PMID: 28121921 DOI: 10.1097/MD.0000000000005647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
5 Hassnine AA, Soliman W, Elsayed AM, Higazi MM, Saied M, Abdelraheem EM. Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00181-4] [Reference Citation Analysis]
6 Abo-Amer YE, Abd-Elsalam S, Eldosoky H, ELShenawy AK, Awny S, Elagawy W, Abgeegy ME, Elsergany HF, Elashry H, Negm MS. Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt. Infect Drug Resist 2018;11:2435-41. [PMID: 30538509 DOI: 10.2147/IDR.S183462] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 . Prior to the Oral Therapy, What Do We Know About HCV-4 in Egypt: A Randomized Survey of Prevalence and Risks Using Data Mining Computed Analysis. Medicine (Baltimore) 2015;94:1. [PMID: 25803732 DOI: 10.1097/01.md.0000460806.85095.df] [Reference Citation Analysis]
8 Elrazek A, Saab S, Foad M, Elgohary EA, Sallam MM, Nawara A, Ismael A, Morsi SS, Salah A, Alboraie M, Bhagavathula AS, Zayed M, Elmasry H, Salem TZ. Ongoing Transmission of HCV: Should Cesarean Section be Justified? Data Mining Discovery. J Transl Int Med 2017;5:27-33. [PMID: 28680836 DOI: 10.1515/jtim-2017-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Tag-Adeen M, Alsenbesy M, Ghweil AA, Abd Elrazek MAH, Elgohary EA, Sallam MM, Ismael A, Nawara A. Liver stiffness measurement and spleen diameter as predictors for the presence of esophageal varices in chronic hepatitis C patients. Medicine (Baltimore) 2017;96:e8621. [PMID: 29145280 DOI: 10.1097/MD.0000000000008621] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
10 Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 2016;3:e000112. [PMID: 27752338 DOI: 10.1136/bmjgast-2016-000112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
11 Ahmed OA, Safwat E, Khalifa MO, Elshafie AI, Fouad MHA, Salama MM, Naguib GG, Eltabbakh MM, Sherief AF, Abd-Elsalam S. Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. Int J Hepatol 2018;2018:9616234. [PMID: 29755792 DOI: 10.1155/2018/9616234] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
12 Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J 2018;15:180. [PMID: 30466446 DOI: 10.1186/s12985-018-1094-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
13 Abd Elrazek AE, Shehab A, Elnour AA, Al Nuaimi SK, Baghdady S. Colon in the chest: an incidental dextrocardia: a case report study. Medicine (Baltimore) 2015;94:e507. [PMID: 25674744 DOI: 10.1097/MD.0000000000000507] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]